neotiv GmbH

neotiv GmbH is a technology-oriented company providing a digital platform with cognitive assessments aimed at early detection and monitoring of memory disorders, particularly Alzheimer’s disease. Founded in 2017 in Magdeburg, Germany, neotiv GmbH focuses on developing cognitive testing solutions for healthcare applications. The company was established by a team of six founders, including Chris Rehse, who has a background in health technology innovation. Notably, neotiv has completed two funding deals, with the most recent on October 4, 2022, raising EUR 10 million led by IBG Innovationsfonds, along with participation from Capricorn Partners, High-Tech Gründerfonds, and other investors.

The total amount raised by the company currently stands at EUR 10 million, and its latest valuation is EUR 107. 859 million. neotiv offers a digital platform featuring innovative cognitive tests tailored for the early medical assessment and ongoing monitoring of memory issues, particularly in the context of Alzheimer’s disease. Their primary products include user-friendly cognitive tests that assess visual memory, customizable health questionnaires, and neuropsychological tests.

These tools enable longitudinal analysis of memory performance for various applications in research, clinical diagnosis, and drug development. The platform is utilized by healthcare professionals, researchers, and clinical trial participants across international markets, including Europe and North America, and supports both on-site and mobile assessments through dedicated applications. Collaborations with leading scientists bolster the continual validation and refinement of their products, enhancing reliability and integration into medical practices. neotiv generates revenue primarily through a subscription-based model, allowing healthcare providers and researchers to access its digital platform and cognitive testing tools.

This transactional approach caters to various applications, including clinical trials and patient assessments. The firm partners with hospitals and research institutions to tailor its platform to specific study requirements while ensuring comprehensive data collection and analysis capabilities. Their pricing plans accommodate different levels of access for individual practitioners and larger institutions alike, with the neotivTrials platform positioned as a flagship offering that emphasizes support for cognitive health research and patient-centered care. In October 2022, neotiv GmbH raised EUR 10 million in venture funding to accelerate its product development efforts.

The company aims to enhance its existing digital platform and introduce new products designed specifically for memory assessments. Targeting expansion into additional international markets, neotiv plans to focus on regions in Europe and North America, leveraging the recent funding to support these growth initiatives. The investment will facilitate the acceleration of product advancements and broaden their market reach, ultimately advancing the company’s mission to improve cognitive health assessments.